CG Oncology (NASDAQ:CGON) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.41) by 9.76 percent. This is a 25 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $52.00 thousand which missed the analyst consensus estimate of $212.75 thousand by 75.56 percent. This is a 90.17 percent decrease over sales of $529.00 thousand the same period last year.